The Saudi Food and Drug Authority (SFDA) has granted approval to BRUKINSA (zanubrutinib), a joint venture by BeiGene and NewBridge Pharmaceuticals, for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received a prior therapy. Upon...
Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment...
